According to the Zhitong Finance APP, DAJIAWEIKANG (301126.SZ) announced that its wholly-owned subsidiary, DAJIAWEIKANG Biopharmaceutical Co., Ltd., has received the "Drug Registration Certificate" for Azithromycin Dry Suspension approved and issued by the National Medical Products Administration.

The indications for Azithromycin Dry Suspension include the following: Azithromycin is a macrolide antibiotic suitable for the treatment of mild to moderate infections caused by specified microbial sensitive strains in the following specific conditions: 1. Acute exacerbation of bacterial infection in chronic bronchitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae; 2. Community-acquired pneumonia caused by Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae; 3. Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae; 4. Acute bacterial sinusitis caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae; 5. Pharyngitis/tonsillitis caused by Streptococcus pyogenes; 6. Simple skin and skin structure infections caused by Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae; 7. Urethritis and cervicitis caused by Chlamydia trachomatis or Neisseria gonorrhoeae; 8. Male genital ulcer disease (chancroid) caused by Haemophilus ducreyi. Due to the low number of women recruited in clinical trials, the efficacy of Azithromycin in treating female chancroid has not yet been determined